• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Human Vaccines Market Size

    ID: MRFR/Pharma/1984-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North Ame...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Human Vaccines Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Human Vaccines Size

    Human Vaccines Market Growth Projections and Opportunities

    The human vaccines market is impacted by many factors that in combination define its development, which reflects ongoing changes in the incidence of contagious diseases and intervening technologies on a global scale. One of the main catalysts for the human vaccines market is global focus on disease prevention via immunization programs. Nevertheless governments, international organizations and public health agencies operate together on vaccination programs that address several infectious diseases stimulating further demand for the vaccine. Recent pandemics such as COVID-19 have made pandemic preparedness one of the hottest topics in global health. This has led to increased investment in vaccine research, development and production capacities leading inevitably to an increased demand for vaccines against these new viral perils. The market has been profoundly influenced by the constant development of vaccine technology. Revolutionary breakthroughs in mRNA, viral vector and recombinant DNA technologies have opened the path for development of novel innovative vaccines with improved efficacy, safety profiles as well rapid production which serve to benefit growth prospects. The growing campaigns to widen immunization coverage worldwide, particularly in low- and middle-income countries contributes into the development of human vaccines market. International cooperations and partnerships seek to offset restrictions in the accessibility of vaccines, reaching further into preventive immunization. Infectious diseases and the subsequent emergence of new pathogens impact vaccine demand. The emergence of novel infectious threats, or the return to vaccine preventable diseases results in research and development endeavour that would formulate effective vaccines against increasing challenges. Vaccine research and development is effectively fueled by significant governmental funding and support. Public-private partnerships and government risk sharing mechanisms help vaccine manufacturers receive financial incentives, which in turn leads to development of new innovative vaccines as well as timely introduction of such innovations into the market. Increased interest in the benefits of vaccination and public health education initiatives promote greater acceptance by people. Education on the prospect of immunization to prevent infectious diseases promote uptake and improve market demand. There is also increased vulnerability to infections among older adults due to the aging global population and increasing prevalence of chronic diseases The demand of vaccines used on this age group such as influenza and pneumonia vaccine witnesses growth due to which the market expands. The widespread use of vaccines in travel medicine, founded on the growing popularity of global traveling, contributes to market development.

    Human Vaccines Market Size Graph

    Market Summary

    As per Market Research Future Analysis, the Human Vaccines Market is projected to grow significantly, driven by the increasing prevalence of infectious diseases and heightened public awareness of vaccination benefits. The market is expected to expand from 50.22 USD Billion in 2025 to 1.23 USD Billion by 2035, reflecting a CAGR of 4.14% during the forecast period. Key drivers include substantial investments in research and development, public-private partnerships, and advancements in vaccine technology, such as mRNA and personalized vaccines.

    Key Market Trends & Highlights

    The Global Human Vaccines Market is witnessing transformative trends that are shaping its future.

    • Market Size in 2024: 0.67 USD Billion; Expected to reach 1.23 USD Billion by 2035. Inactivated vaccines valued at 15.0 USD Billion in 2024, projected to grow to 23.0 USD Billion by 2035. Public awareness campaigns have increased immunization coverage for DTP vaccines to over 85% globally. North America leads the market with a valuation of 20.0 USD Billion in 2024, expected to grow to 32.0 USD Billion by 2035.

    Market Size & Forecast

    2024 Market Size USD 0.67 Billion
    2035 Market Size USD 1.23 Billion
    CAGR (2025-2035) 5.72%
    Largest Regional Market Share in 2024 North America.

    Major Players

    <p>Key Companies include Pfizer, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi.</p>

    Market Trends

    The Global Human Vaccines Market is witnessing significant trends driven by various market factors. A key market driver is the increasing prevalence of infectious diseases and the need for preventative healthcare measures. With growing awareness of vaccination benefits, governments and healthcare organizations are investing in vaccination programs to prevent outbreaks and enhance public health. 

    This heightened focus on preventive healthcare is leading nations to support initiatives aimed at increasing vaccination coverage and developing innovative vaccines. Opportunities to be explored in this market include advancements in vaccine technology, such as mRNA technology and personalized vaccines.

    As researchers continue to innovate, there is potential for the introduction of new and effective vaccine formulations that cater to specific populations and evolving pathogens. Furthermore, as global travel increases and disease patterns change, there is an increasing demand for vaccines that address emerging infectious diseases, presenting a chance for companies to develop specialized products. 

    In recent times, trends show a significant increase in public-private partnerships to facilitate vaccine research and distribution, as seen during the COVID-19 pandemic. This collaboration has not only expedited vaccine development timelines but has also highlighted the importance of global cooperation in addressing health crises.

    Furthermore, the push towards universal vaccination programs to ensure equitable access across diverse populations has gained momentum, reflecting a commitment to global health security. Overall, these trends underscore a dynamic environment where innovation, collaboration, and public health priorities shape the future of the Global Human Vaccines Market.

     

    <p>The Global Human Vaccines Market is poised for robust growth, driven by increasing public health initiatives and a heightened focus on preventive healthcare measures.</p>

    World Health Organization (WHO)

    Human Vaccines Market Market Drivers

    Increasing Global Vaccination Coverage

    The Global Human Vaccines Market Industry is experiencing growth due to the increasing emphasis on vaccination coverage across various populations. Governments worldwide are implementing policies aimed at enhancing immunization rates, particularly in developing regions. For instance, initiatives by the World Health Organization focus on achieving universal vaccination coverage, which is projected to significantly impact market dynamics. As of 2024, the market is valued at approximately 48.2 USD Billion, reflecting the importance of vaccination in public health strategies. This trend is expected to continue, with a projected market value of 78.5 USD Billion by 2035, indicating a sustained commitment to improving global health outcomes.

    Market Segment Insights

    Human Vaccines Market Vaccine Type Insights

    <p>The Global Human Vaccines Market is poised for considerable growth, with a notable focus on the Vaccine Type segment, which includes various classifications like Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines. The overall market is expected to witness a substantial rise, with projections indicating a value of 50.22 USD Billion in 2024 and reaching 78.5 USD Billion by 2035. Within this landscape, the Inactivated segment holds the majority, valued at 15.0 USD Billion in 2024 and projected to grow to 23.0 USD Billion by 2035.</p>

    <p>This segment is vital due to its effectiveness in immunizing against a range of diseases without causing the infection itself, making it a safe choice for broad population use. Following closely is the Live Attenuated segment, expected to be valued at 10.0 USD Billion in 2024 and rise to 15.5 USD Billion by 2035. Live Attenuated vaccines are significant as they offer robust immunity and often require fewer doses, thereby ensuring better compliance among different demographics.&nbsp;</p>

    <p>The Subunit vaccines are valued at 8.0 USD Billion in 2024, increasing to 12.0 USD Billion by 2035, which makes them critical due to their ability to use only specific parts of the virus or bacteria, reducing side effects while maintaining efficacy.</p>

    Human Vaccines Market Application Insights

    <p>This segment encompasses critical applications including Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Influenza Vaccines. Preventive Vaccines are crucial in preventing infectious diseases, thus significantly impacting global health outcomes. Furthermore, Therapeutic Vaccines are gaining traction in treating chronic diseases and cancers, leading to innovations in Research and Development.</p>

    <p>Travel Vaccines cater to health-conscious travelers, promoting safety and disease prevention across borders, while Influenza Vaccines remain essential given the seasonal outbreaks, ensuring community health is prioritized. With such diverse applications, the Global Human Vaccines Market revenue is set to expand, backed by rising public health initiatives and awareness around vaccine benefits, despite challenges such as logistics and public skepticism. Understanding this landscape through Global Human Vaccines Market segmentation is vital for stakeholders to harness opportunities and enhance vaccine accessibility.</p>

    Human Vaccines Market Administration Route Insights

    <p>The Administration Route plays a crucial role in this market, as it encompasses various methods used to deliver vaccines effectively. This segmentation includes routes such as Intramuscular, Subcutaneous, Oral, and Intradermal administration, each of which presents unique advantages. Intramuscular administration is particularly notable for its rapid immune response, making it a preferred choice for many vaccines, including those targeting diseases like influenza and COVID-19</p>

    <p>.Subcutaneous routes are gaining traction due to their ease of administration, especially for patients who require self-administration. Oral vaccination presents an innovative approach that can improve accessibility and adherence, while Intradermal administration is being explored for its potential to reduce vaccine dosages and improve immunogenicity. As the Global Human Vaccines Market data shows, the increasing focus on vaccination programs worldwide, along with advances in vaccine delivery technologies, is a driving force behind the growth and significance of these administration routes.</p>

    <p>The ongoing challenges of vaccine hesitancy and logistical issues create pathways for innovative solutions in this sector. The Global Human Vaccines Market statistics suggest that the various administration methods are integral to achieving widespread vaccine coverage and combating infectious diseases on a global scale.</p>

    Human Vaccines Market Target Diseases Insights

    <p>The landscape is primarily shaped by various diseases, including Infectious Diseases, Oncological Diseases, and Autoimmune Diseases. <a href="https://www.marketresearchfuture.com/reports/infectious-disease-drug-market-43143">Infectious Disease vaccines</a> remain crucial due to their role in preventing outbreaks and protecting public health, while Oncological Diseases vaccines are gaining importance in cancer prevention and treatment, reflecting advancements in Research and Development.</p>

    <p>Autoimmune Diseases, often complex and diverse, present significant challenges for vaccine development yet represent a growing area of interest for addressing chronic health issues. The increasing prevalence of these diseases, coupled with technological advancements and a growing understanding of the immune system, contributes to the market growth. With a compound annual growth rate of 4.14 expected for the period from 2025 to 2035, the sector is well-positioned to adapt to emerging health challenges while continuously making strides in vaccine effectiveness and safety.</p>

    <p>The Global Human Vaccines Market statistics indicate a trend toward personalized and targeted therapies, emphasizing the importance of addressing diverse health needs on a global scale.</p>

    Get more detailed insights about Human Vaccines Market Research Report - Forecast to 2034

    Regional Insights

    The Global Human Vaccines Market is characterized by diverse regional dynamics shaping its growth trajectory. In 2024, North America leads with a valuation of 20.0 USD Billion, expected to grow to 32.0 USD Billion by 2035, reflecting significant investments in Research and Development and robust healthcare infrastructure. Europe follows with a market value of 12.5 USD Billion in 2024, projected to rise to 20.0 USD Billion, highlighting the region's focus on innovation and advanced immunization strategies. 

    The Asia-Pacific (APAC) region is projected to reach 10.0 USD Billion in 2024, with growth anticipated to 15.0 USD Billion, driven by a rapidly expanding population and increasing healthcare accessibility.South America is valued at 4.0 USD Billion in 2024, growing to 6.0 USD Billion, showcasing improvements in vaccination coverage amidst economic advancements. The Middle East and Africa (MEA) hold a current market value of 3.72 USD Billion, progressing to 5.5 USD Billion, as investments in healthcare infrastructure rise, enhancing vaccine delivery systems. 

    The dominance of North America, in particular, underscores the significant role of regulatory frameworks and funding in vaccine development, while the growth in APAC indicates a burgeoning demand for vaccines amid increasing healthcare expenditure.

    Human Vaccines Market Segment

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Global Human Vaccines Market is characterized by robust competition and constant innovation, driven by the critical importance of vaccines in preventing diseases and safeguarding public health. As the market expands, various pharmaceutical companies vie for leadership, investing heavily in research and development to create more effective vaccine solutions. 

    Factors such as increasing prevalence of infectious diseases, emerging global health threats, and the rising demand for vaccines worldwide are shaping the competitive landscape. As a result, companies are not only focusing on advanced research but also forming strategic alliances and partnerships, which enhance their capabilities in delivering innovative vaccine options to meet global health needs.

    Pfizer has established itself as a formidable player in the Global Human Vaccines Market, underpinned by its extensive portfolio and deep-rooted commitment to vaccine development. The company’s strengths lie in its advanced technological platforms and strong RD capabilities, which allow it to deliver a wide range of vaccines targeting various infectious diseases.

     Pfizer’s global presence is reinforced through its strategic partnerships, collaborations with healthcare organizations, and robust distribution networks, enabling it to reach diverse markets effectively. The company's significant investment in innovative vaccine research has resulted in breakthroughs that have addressed urgent global health concerns, further solidifying its position in the competitive landscape.

    Merck and Co a significant footprint in the Global Human Vaccines Market, focusing on the development of innovative vaccines and therapeutic solutions for infectious diseases. Renowned for its key products, Merck offers vaccines that target diseases such as HPV, measles, and influenza. The company has been proactive in expanding its market presence through strategic mergers and acquisitions, allowing it to integrate novel technologies and enhance its research capabilities. 

    Merck’s strong emphasis on vaccine development is reflected in its commitment to global health initiatives aimed at increasing accessibility and expanding immunization programs. Its well-established reputation for high-quality products and strong pipeline of vaccine candidates positions Merck as a leader in the market committed to advancing public health through continuous innovation and responsive product offerings.

    Key Companies in the Human Vaccines Market market include

    Industry Developments

    Recent developments in the Global Human Vaccines Market have been significantly influenced by various factors, including the ongoing response to infectious diseases and advancements in vaccine technology. In October 2023, Pfizer announced a collaboration with Moderna to enhance mRNA vaccine production efficiency, reflecting an industry trend toward partnerships for rapid vaccine development. Meanwhile, Merck and Co confirmed their investment in next-generation vaccine platforms to combat emerging pathogens, showcasing a commitment to innovation in vaccine efficacy and safety.

    Currently, companies like Gilead Sciences and Johnson and Johnson are focusing on expanding their pipeline, especially in therapeutic vaccines targeting HIV and cancer, while Roche and Novartis are investing in biopharmaceuticals to enhance immunogenicity. Notably, GlaxoSmithKline has reported a substantial increase in vaccine sales, attributing this to rising vaccination rates globally.

    In the past two to three years, the market has seen significant growth due to increased vaccination campaigns, particularly against COVID-19, with AstraZeneca and Sanofi making strides in vaccine distribution. The combined efforts of these leading firms illustrate a dynamic landscape in the Global Human Vaccines Market, emphasizing innovation and strategic collaborations to address public health challenges.

    Future Outlook

    Human Vaccines Market Future Outlook

    <p>The Human Vaccines Market is projected to grow at a 5.72% CAGR from 2025 to 2035, driven by technological advancements, increasing vaccination awareness, and expanding global health initiatives.</p>

    New opportunities lie in:

    • <p>Invest in mRNA vaccine technology for rapid response to emerging pathogens. Develop combination vaccines to enhance immunization coverage and patient compliance. Leverage digital health platforms for vaccine tracking and patient engagement.</p>

    <p>By 2035, the Human Vaccines Market is expected to be robust, reflecting substantial advancements and increased global health commitments.</p>

    Market Segmentation

    Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Human Vaccines Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Human Vaccines Market Application Outlook

    • Preventive Vaccines
    • Therapeutic Vaccines
    • Travel Vaccines
    • Influenza Vaccines

    Human Vaccines Market Vaccine Type Outlook

    • Inactivated
    • Live Attenuated
    • Subunit
    • Recombinant
    • Toxoid

    Human Vaccines Market Target Diseases Outlook

    • Infectious Diseases
    • Oncological Diseases
    • Autoimmune Diseases

    Human Vaccines Market Administration Route Outlook

    • Intramuscular
    • Subcutaneous
    • Oral
    • Intradermal

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024 48.22(USD Billion)
    Market Size 2025 50.22(USD Billion)
    Market Size 2035 1.23 (USD Billion)
    Compound Annual Growth Rate (CAGR) 5.72% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled Pfizer, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi
    Segments Covered Vaccine Type, Application, Administration Route, Target Diseases, Regional
    Key Market Opportunities Rising infectious disease outbreaks, Increasing vaccination awareness, Expansion of vaccine pipelines, Growth in healthcare funding, Advancements in vaccine technology
    Key Market Dynamics Increasing vaccine demand, Technological advancements, Government support and funding, Global health initiatives, Rising infectious diseases.
    Countries Covered North America, Europe, APAC, South America, MEA

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the projected market size of the Global Human Vaccines Market by 2035?

    The Global Human Vaccines Market is expected to be valued at 78.5 USD Billion by 2035.

    What is the expected compound annual growth rate (CAGR) for the Global Human Vaccines Market from 2025 to 2035?

    The expected CAGR for the Global Human Vaccines Market from 2025 to 2035 is 4.14%.

    Which region is projected to hold the largest market share in the Global Human Vaccines Market by 2035?

    North America is projected to hold the largest market share, valued at 32.0 USD Billion by 2035.

    What will be the market size of Inactivated vaccines in the Global Human Vaccines Market by 2035?

    The market size for Inactivated vaccines is expected to reach 23.0 USD Billion by 2035.

    Who are the major players in the Global Human Vaccines Market?

    Major players in the Global Human Vaccines Market include Pfizer, Merck and Co, AbbVie, and Roche among others.

    What is the expected market value for the Live Attenuated vaccine segment by 2035?

    The Live Attenuated vaccine segment is expected to reach a market value of 15.5 USD Billion by 2035.

    How much is the market for Subunit vaccines expected to grow by 2035?

    The market for Subunit vaccines is projected to grow to 12.0 USD Billion by 2035.

    What is the projected market value of the Global Human Vaccines Market in 2024?

    The projected market value of the Global Human Vaccines Market in 2024 is 50.22 USD Billion.

    What is the expected market value for the Toxoid vaccine segment by 2035?

    The Toxoid vaccine segment is anticipated to reach a market value of 11.0 USD Billion by 2035.

    How will the APAC region's market size change from 2024 to 2035?

    The market size in the APAC region is expected to grow from 10.0 USD Billion in 2024 to 15.0 USD Billion by 2035.

    1. --- "
    2. Table of Contents
    3. EXECUTIVE SUMMARY
    4. Market Overview
    5. Key Findings
    6. Market Segmentation
    7. Competitive Landscape
    8. Challenges and Opportunities
    9. Future Outlook
    10. MARKET INTRODUCTION
    11. Definition
    12. Scope of the study
    13. Research Objective
    14. Assumption
    15. Limitations
    16. RESEARCH METHODOLOGY
    17. Overview
    18. Data Mining
    19. Secondary Research
    20. Primary Research
    21. Primary Interviews and Information Gathering Process
    22. Breakdown of Primary Respondents
    23. Forecasting Model
    24. Market Size Estimation
    25. Bottom-Up Approach
    26. Top-Down Approach
    27. Data Triangulation
    28. Validation
    29. MARKET DYNAMICS
    30. Overview
    31. Drivers
    32. Restraints
    33. Opportunities
    34. MARKET FACTOR ANALYSIS
    35. Value chain Analysis
    36. Porter's Five Forces Analysis
    37. Bargaining Power of Suppliers
    38. Bargaining Power of Buyers
    39. Threat of New Entrants
    40. Threat of Substitutes
    41. Intensity of Rivalry
    42. COVID-19 Impact Analysis
    43. Market Impact Analysis
    44. Regional Impact
    45. Opportunity and Threat Analysis
    46. Human Vaccines Market, BY Vaccine Type (USD Billion)
    47. Inactivated
    48. Live Attenuated
    49. Subunit
    50. Recombinant
    51. Toxoid
    52. Human Vaccines Market, BY Application (USD Billion)
    53. Preventive Vaccines
    54. Therapeutic Vaccines
    55. Travel Vaccines
    56. Influenza Vaccines
    57. Human Vaccines Market, BY Administration Route (USD Billion)
    58. Intramuscular
    59. Subcutaneous
    60. Oral
    61. Intradermal
    62. Human Vaccines Market, BY Target Diseases (USD Billion)
    63. Infectious Diseases
    64. Oncological Diseases
    65. Autoimmune Diseases
    66. Human Vaccines Market, BY Regional (USD Billion)
    67. North America
    68. US
    69. Canada
    70. Europe
    71. Germany
    72. UK
    73. France
    74. Russia
    75. Italy
    76. Spain
    77. Rest of Europe
    78. APAC
    79. China
    80. India
    81. Japan
    82. South Korea
    83. Malaysia
    84. Thailand
    85. Indonesia
    86. Rest of APAC
    87. South America
    88. Brazil
    89. Mexico
    90. Argentina
    91. Rest of South America
    92. MEA
    93. GCC Countries
    94. South Africa
    95. Rest of MEA
    96. Competitive Landscape
    97. Overview
    98. Competitive Analysis
    99. Market share Analysis
    100. Major Growth Strategy in the Human Vaccines Market
    101. Competitive Benchmarking
    102. Leading Players in Terms of Number of Developments in the Human Vaccines Market
    103. Key developments and growth strategies
    104. New Product Launch/Service Deployment
    105. Merger & Acquisitions
    106. Joint Ventures
    107. Major Players Financial Matrix
    108. Sales and Operating Income
    109. Major Players R&D Expenditure. 2023
    110. Company Profiles
    111. Pfizer
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. Merck and Co
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. AbbVie
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Roche
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Gilead Sciences
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Johnson and Johnson
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. Bristol Myers Squibb
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. Novartis
    154. Financial Overview
    155. Products Offered
    156. Key Developments
    157. SWOT Analysis
    158. Key Strategies
    159. Regeneron Pharmaceuticals
    160. Financial Overview
    161. Products Offered
    162. Key Developments
    163. SWOT Analysis
    164. Key Strategies
    165. Bayer
    166. Financial Overview
    167. Products Offered
    168. Key Developments
    169. SWOT Analysis
    170. Key Strategies
    171. Moderna
    172. Financial Overview
    173. Products Offered
    174. Key Developments
    175. SWOT Analysis
    176. Key Strategies
    177. AstraZeneca
    178. Financial Overview
    179. Products Offered
    180. Key Developments
    181. SWOT Analysis
    182. Key Strategies
    183. GlaxoSmithKline
    184. Financial Overview
    185. Products Offered
    186. Key Developments
    187. SWOT Analysis
    188. Key Strategies
    189. Sanofi
    190. Financial Overview
    191. Products Offered
    192. Key Developments
    193. SWOT Analysis
    194. Key Strategies
    195. Appendix
    196. References
    197. Related Reports

    Human Vaccines Market Segmentation

    Human Vaccines Market By Vaccine Type (USD Billion, 2019-2035)

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    Human Vaccines Market By Application (USD Billion, 2019-2035)

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    Human Vaccines Market By Administration Route (USD Billion, 2019-2035)

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    Human Vaccines Market By Target Diseases (USD Billion, 2019-2035)

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    Human Vaccines Market By Regional (USD Billion, 2019-2035)

    North America

    Europe

    South America

    Asia Pacific

    Middle East and Africa

    Human Vaccines Market Regional Outlook (USD Billion, 2019-2035)

    North America Outlook (USD Billion, 2019-2035)

    North America Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    North America Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    North America Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    North America Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    North America Human Vaccines Market by Regional Type

    US

    Canada

    US Outlook (USD Billion, 2019-2035)

    US Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    US Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    US Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    US Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    CANADA Outlook (USD Billion, 2019-2035)

    CANADA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    CANADA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    CANADA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    CANADA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    Europe Outlook (USD Billion, 2019-2035)

    Europe Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    Europe Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    Europe Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    Europe Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    Europe Human Vaccines Market by Regional Type

    Germany

    UK

    France

    Russia

    Italy

    Spain

    Rest of Europe

    GERMANY Outlook (USD Billion, 2019-2035)

    GERMANY Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    GERMANY Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    GERMANY Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    GERMANY Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    UK Outlook (USD Billion, 2019-2035)

    UK Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    UK Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    UK Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    UK Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    FRANCE Outlook (USD Billion, 2019-2035)

    FRANCE Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    FRANCE Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    FRANCE Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    FRANCE Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    RUSSIA Outlook (USD Billion, 2019-2035)

    RUSSIA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    RUSSIA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    RUSSIA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    RUSSIA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    ITALY Outlook (USD Billion, 2019-2035)

    ITALY Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    ITALY Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    ITALY Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    ITALY Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    SPAIN Outlook (USD Billion, 2019-2035)

    SPAIN Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    SPAIN Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    SPAIN Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    SPAIN Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    REST OF EUROPE Outlook (USD Billion, 2019-2035)

    REST OF EUROPE Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    REST OF EUROPE Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    REST OF EUROPE Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    REST OF EUROPE Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    APAC Outlook (USD Billion, 2019-2035)

    APAC Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    APAC Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    APAC Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    APAC Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    APAC Human Vaccines Market by Regional Type

    China

    India

    Japan

    South Korea

    Malaysia

    Thailand

    Indonesia

    Rest of APAC

    CHINA Outlook (USD Billion, 2019-2035)

    CHINA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    CHINA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    CHINA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    CHINA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    INDIA Outlook (USD Billion, 2019-2035)

    INDIA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    INDIA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    INDIA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    INDIA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    JAPAN Outlook (USD Billion, 2019-2035)

    JAPAN Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    JAPAN Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    JAPAN Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    JAPAN Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    SOUTH KOREA Outlook (USD Billion, 2019-2035)

    SOUTH KOREA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    SOUTH KOREA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    SOUTH KOREA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    SOUTH KOREA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    MALAYSIA Outlook (USD Billion, 2019-2035)

    MALAYSIA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    MALAYSIA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    MALAYSIA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    MALAYSIA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    THAILAND Outlook (USD Billion, 2019-2035)

    THAILAND Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    THAILAND Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    THAILAND Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    THAILAND Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    INDONESIA Outlook (USD Billion, 2019-2035)

    INDONESIA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    INDONESIA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    INDONESIA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    INDONESIA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    REST OF APAC Outlook (USD Billion, 2019-2035)

    REST OF APAC Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    REST OF APAC Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    REST OF APAC Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    REST OF APAC Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    South America Outlook (USD Billion, 2019-2035)

    South America Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    South America Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    South America Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    South America Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    South America Human Vaccines Market by Regional Type

    Brazil

    Mexico

    Argentina

    Rest of South America

    BRAZIL Outlook (USD Billion, 2019-2035)

    BRAZIL Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    BRAZIL Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    BRAZIL Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    BRAZIL Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    MEXICO Outlook (USD Billion, 2019-2035)

    MEXICO Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    MEXICO Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    MEXICO Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    MEXICO Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    ARGENTINA Outlook (USD Billion, 2019-2035)

    ARGENTINA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    ARGENTINA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    ARGENTINA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    ARGENTINA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

    REST OF SOUTH AMERICA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    REST OF SOUTH AMERICA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    REST OF SOUTH AMERICA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    REST OF SOUTH AMERICA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    MEA Outlook (USD Billion, 2019-2035)

    MEA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    MEA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    MEA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    MEA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    MEA Human Vaccines Market by Regional Type

    GCC Countries

    South Africa

    Rest of MEA

    GCC COUNTRIES Outlook (USD Billion, 2019-2035)

    GCC COUNTRIES Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    GCC COUNTRIES Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    GCC COUNTRIES Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    GCC COUNTRIES Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    SOUTH AFRICA Outlook (USD Billion, 2019-2035)

    SOUTH AFRICA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    SOUTH AFRICA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    SOUTH AFRICA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    SOUTH AFRICA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    REST OF MEA Outlook (USD Billion, 2019-2035)

    REST OF MEA Human Vaccines Market by Vaccine Type

    Inactivated

    Live Attenuated

    Subunit

    Recombinant

    Toxoid

    REST OF MEA Human Vaccines Market by Application Type

    Preventive Vaccines

    Therapeutic Vaccines

    Travel Vaccines

    Influenza Vaccines

    REST OF MEA Human Vaccines Market by Administration Route Type

    Intramuscular

    Subcutaneous

    Oral

    Intradermal

    REST OF MEA Human Vaccines Market by Target Diseases Type

    Infectious Diseases

    Oncological Diseases

    Autoimmune Diseases

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027